PURE Bioscience, Inc. (OTCMKTS:PURE) Sees Large Drop in Short Interest

PURE Bioscience, Inc. (OTCMKTS:PURE) saw a significant decrease in short interest in November. As of November 15th, there was short interest totalling 14,500 shares, a decrease of 68.9% from the October 31st total of 46,600 shares. Based on an average trading volume of 80,600 shares, the short-interest ratio is presently 0.2 days.

PURE Bioscience Price Performance

OTCMKTS PURE traded down $0.01 during trading hours on Wednesday, hitting $0.09. The company had a trading volume of 40,845 shares, compared to its average volume of 28,709. The firm’s 50 day moving average is $0.09 and its 200 day moving average is $0.08. PURE Bioscience has a fifty-two week low of $0.06 and a fifty-two week high of $0.17. The company has a market capitalization of $9.72 million, a price-to-earnings ratio of -2.46 and a beta of 0.05.

PURE Bioscience (OTCMKTS:PURE) last posted its earnings results on Tuesday, October 29th. The company reported ($0.01) earnings per share (EPS) for the quarter. The firm had revenue of $0.47 million during the quarter.

PURE Bioscience Company Profile

PURE Bioscience, Inc develops and commercializes antimicrobial products that provide solutions to the health and environmental challenges of pathogen and hygienic control in the United States and internationally. The company manufactures and distributes silver dihydrogen citrate (SDC), a non-toxic antimicrobial agent, which offers residual protection, as well as formulates with other compounds.